Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eddingpharma to Start China Trial of Cardiome AFib Drug

publication date: Jul 24, 2015
Eddingpharm, a China in-licensing company, plans to start a China Phase I trial of Brinavess, a drug developed by Cardiome Pharma of Canada to treat atrial fibrillation. Eddingpharm will conduct the Phase I trial in healthy volunteers and then proceed to a Phase III trial, which it expects will begin before year-end. Eddingpharm in-licensed the drug in late 2014, paying $1 million upfront and agreeing to an additional $3 million in milestones. More details....

Stock Symbol: (NSDQ: CRME)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital